Lymphatic endothelial cells Sample Clauses

Lymphatic endothelial cells. With the relatively recent discovery of specific markers for LECs in humans and mice such as LYVE-1 (134), podoplanin (193), and VEGFR3 (194); research in this field has grown. Pure populations of LEC can be isolated from a variety of tissue types and pathologies, allowing elucidation of their functionality, in particular their ability to regulate the adaptive immune response (reviewed in (122)). LECs express MHC class I and can present self-antigen to CD8+ T cells for tolerance induction in non-transplant models (195, 196). Lymph node LEC (LN-LEC) express high levels of the co-inhibitory molecule PDL1, and low levels of the classic co-stimulatory molecules CD80 and CD86. The absence of sufficient co-stimulatory signals leads to upregulation of PD1 on CD8+ T cells and subsequent engagement with PDL1 on LEC in the lymph node leading to CD8+ T cell deletion (196). Therefore, LECs contribute to peripheral tolerance by inducing CD8+ T cell deletion via PDL1. Lymph nodes have been found to be an important site for self-tolerance induction, with many lymph node stromal cell types (including LEC) having the ability to directly present self-antigen and induce CD8+ T cell deletion (197). In a melanoma model, tumour expression of VEGF-C was found to promote immune tolerance of tumours by the host. Local tumour-specific CD8+ T cells were deleted, and LN-LECs were able to cross-present tumour antigen, and drive CD8+ T cell proliferation and apoptosis ex vivo (198). LEC-mediated induction of CD4+ T cell tolerance is less well characterised, although some progress has been made. It appears that CD4+ T cell self-tolerance induction is mediated by interaction with DCs. MHC class II expression by LECs is under the control of the IFN-γ inducible promoter IV, therefore its expression is minimal in steady-state conditions. Xxxxxx et al. found that LECs acquire antigenic peptide-MHC class II complexes from DCs as a result of cell-cell contact and exosomes (199). These acquired complexes are presented to cognate CD4+ T cells, resulting in CD4+ T cell dysfunction and resistance to further stimulation. Others have found that LEC can act as antigen reservoirs for DCs (200). Although LECs do express MHC class II (albeit minimally), they cannot load endogenous peptides onto MHC II molecules due to the lack of H2-M. Therefore, they transfer endogenous peptides to DCs, which are then loaded onto MHC class II and presented to CD4+ T cells for tolerance induction. It appears that endoge...
AutoNDA by SimpleDocs

Related to Lymphatic endothelial cells

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • COVID-19 Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Study Population Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 230 to be assigned to the study: n = 120 to be analysed: n = 120 Duration of intervention per patient of the intervention group: minimum 21 days/3 weeks until patient’s weight >2000g, averaged 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months following enterostomy closure (12- month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 months of overall study duration).

  • Organ Transplants This plan covers organ and tissue transplants when ordered by a physician, is medically necessary, and is not an experimental or investigational procedure. Examples of covered transplant services include but are not limited to: heart, heart-lung, lung, liver, small intestine, pancreas, kidney, cornea, small bowel, and bone marrow. Allogenic bone marrow transplant covered healthcare services include medical and surgical services for the matching participant donor and the recipient. However, Human Leukocyte Antigen testing is covered as indicated in the Summary of Medical Benefits. For details see Human Leukocyte Antigen Testing section. This plan covers high dose chemotherapy and radiation services related to autologous bone marrow transplantation to the extent required under R.I. Law § 27-20-60. See Experimental or Investigational Services in Section 3 for additional information. To speak to a representative in our Case Management Department please call 1-401- 000-0000 or 1-888-727-2300 ext. 2273. The national transplant network program is called the Blue Distinction Centers for Transplants. SM For more information about the Blue Distinction Centers for TransplantsSM call our Customer Service Department or visit our website. When the recipient is a covered member under this plan, the following services are also covered: • obtaining donated organs (including removal from a cadaver); • donor medical and surgical expenses related to obtaining the organ that are integral to the harvesting or directly related to the donation and limited to treatment occurring during the same stay as the harvesting and treatment received during standard post- operative care; and • transportation of the organ from donor to the recipient. The amount you pay for transplant services, for the recipient and eligible donor, is based on the type of service.

  • Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!